Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1

Vaccine

Volumn 28, Issue 43, 2010, Pages 7047-7053

  Feunou, Pascal Feunou ^a,b   Kammoun, Hana ^a,b   Debrie, Anne Sophie ^a,b   Mielcarek, Nathalie ^a,b   Locht, Camille ^a,b  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

Author keywords

Live attenuated vaccine; Long term immunity; Pertussis

Indexed keywords

BACTERIUM ANTIBODY; BPZE1 VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; INTERLEUKIN 5; PERTUSSIS VACCINE; TETRAVAC; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BACTERIAL VIRULENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTECTION; SPLEEN CELL;

ADMINISTRATION, INTRANASAL; ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, BACTERIAL; BORDETELLA PERTUSSIS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; MICE, SCID; PERTUSSIS VACCINE; SPLEEN; T-LYMPHOCYTES; VACCINES, ATTENUATED; WHOOPING COUGH;

EID: 77957368762     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.017     Document Type: Article

References (31)

1. Von König C.H., Halperin S., Riffelmann M., Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
2. Crowcroft N.S., Stein C., Duclos P., Birmingham M. How best to estimate the global burden of pertussis?. Lancet Infect Dis 2003, 3:418-423.
3. Edwards K.M. Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J 2005, 24(Suppl.):S104-S108.
4. Gustafsson L., Hessel L., Storsaeter J., Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006, 118:978-984.
5. Salmaso S., Mastrantonio P., Wassilak S.G., Giuliano M., Anemona A., Giammanco A., et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine 1998, 16:1270-1275.
6. Rota M.C., Ausiello C.M., D'Amelio R., Cassone A., Giammanco A., Molica C., et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clin Infect Dis 1998, 26:297-302.
7. Giuliano M., Mastrantonio P., Giammanco A., Piscitelli A., Salmaso S., Wassilak S.G. Antibody responses and persistence in the two years after immunization with two acellular and one whole cell vaccine against pertussis. J Pediatrics 1998, 132:983-988.
8. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis. Vaccine 2003, 21:3542-3549.
9. Olin P., Gustafsson L., Barreto L., Hessel L., Mast T.C., Rie A.V., et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003, 21:2015-2021.
10. Mahon B.P., Brady M.T., Mills K.H. Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis 2000, 181:2087-2091.
11. Wearing H.J., Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog 2009, 5:e1000647.
12. Mielcarek N., Debrie A.S., Raze D., Bertout J., Rouanet C., Younes A.B., et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006, 2:e65.
13. Feunou F.P., Bertout J., Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One 2010, 5:e10178.
14. Feunou P.F., Ismaili J., Debrie A.S., Huot L., Hot D., Raze D., et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 2008, 26:5722-5727.
15. Menozzi F.D., Mutombo R., Renauld G., Gantiez C., Hannah J.H., Leininger E., et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect Immun 1994, 62:769-778.
16. Antoine R., Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 1990, 58:1518-1526.
17. Locht C., Geoffroy M.C., Renauld G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbrae share sequence similarities with the papC and papD gene families. EMBO J 1992, 11:3175-3183.
18. Ryan M., Murphy G., Ryan E., Nilsson L., Shackley F., Gothefors L., et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998, 48:1-10.
19. Guiso N., Njamkepo E., Vié le Sage F., Zepp F., Meyer C.U., Abitbol V., et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007, 25:1390-1397.
20. Ausiello C.M., Lande R., Urbani F., la Sala A., Stefanelli P., Salmaso S., et al. Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 1999, 67:4064-4071.
21. Ausiello C.M., Lande R., Urbani F., Di Carlo B., Stefanelli P., Salmaso S., et al. Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 2000, 60:1989-1995.
22. Wendelboe A.M., Van Rie A., Salmaso S., Englund J.A. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005, 24:S58-S61.
23. Mills K.H. Immunity to Bordetella pertussis. Microbes Infect 2001, 3:655-677.
24. Mielcarek N., Debrie A.S., Mahieux S., Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 2010, 17:317-324.
25. Pulendran B., Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006, 124:849-863.
26. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1988, 1:955-960. Ad Hoc Group for the Study of Pertussis Vaccines, [Erratum in: Lancet 1988;1:1238].
27. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998, 181:1901-1906.
28. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334:349-355. Erratum in: N Engl J Med 1996;334:1207.
29. Guiso N., Szatanik M., Rocancourt M Protective activity of Bordetella adenylate cyclase-hemolysin against bacterial colonization. Microb Pathog 1991, 11:423-431.
30. Mills K.H.G., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 1993, 61:399-410.
31. Redhead K., Watkins J., Barnard A., Mills K.H. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 1993, 61:3190-3198.